J Rheum Dis.  2024 Jul;31(3):135-142. 10.4078/jrd.2024.0045.

Overview of childhood vasculitis

• Ahn JG

• KMID: 2557382
• DOI: http://doi.org/10.4078/jrd.2024.0045

Abstract

Pediatric vasculitis and adult vasculitis differ in several aspects. While both involve inflammation of blood vessels, pediatric vasculitis tends to present with distinct clinical features and may involve different types of blood vessels compared to adult vasculitis. Despite its relatively rare occurrence compared to adult vasculitis, pediatric vasculitis warrants careful attention due to its potential for profound and diverse clinical manifestations, ranging from mild cutaneous symptoms to life-threatening systemic complications. Childhood vasculitis should be suspected in children who present symptoms attributable to systemic inflammation and complications arising from multi-organ dysfunction. However, achieving a diagnosis necessitates thorough exclusion of alternative conditions manifesting similar symptoms and findings. Hence, children suspected of vasculitis should undergo meticulous history-taking, comprehensive physical examination, and requisite laboratory investigations, imaging studies, and sometimes tissue biopsies to elucidate the diagnosis. Early detection and treatment of childhood vasculitis are crucial, as the condition can affect various organs and potentially lead to life-threatening complications or long-term sequelae in adulthood if left untreated. This review aimed to provide an exhaustive overview of childhood vasculitis, outlining its epidemiology, classification, clinical presentation, diagnostic modalities, therapeutic strategies and outcome.

Keyword

Vasculitis; Child; Classification; Mucocutaneous lymph node syndrome; IgA vasculitis

Reference

1. Kim GB, Eun LY, Han JW, Kim SH, Yoon KL, Han MY, et al. 2020; Epidemiology of Kawasaki disease in South Korea: a nationwide survey 2015-2017. Pediatr Infect Dis J. 39:1012–6. DOI: 10.1097/INF.0000000000002793. PMID: 33075217.

2. Shim JO, Han K, Park S, Kim GH, Ko JS, Chung JY. 2018; Ten-year nationwide population-based survey on the characteristics of children with Henoch-Schӧnlein purpura in Korea. J Korean Med Sci. 33:e174. DOI: 10.3346/jkms.2018.33.e174. PMID: 29915525. PMCID: PMC6000599.

3. Dolezalová P, Telekesová P, Nemcová D, Hoza J. 2004; Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol. 31:2295–9.

4. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. 2002; Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 360:1197–202. DOI: 10.1016/S0140-6736(02)11279-7. PMID: 12401245.

5. Ozen S, Bakkaloglu A, Dusunsel R, Soylemezoglu O, Ozaltin F, Poyrazoglu H, et al. 2007; Childhood vasculitides in Turkey: a nationwide survey. Clin Rheumatol. 26:196–200. DOI: 10.1007/s10067-006-0266-6. PMID: 16586044.

6. Shulman ST, Rowley AH. 2021; An unintended consequence of pandemic control measures: fewer cases of Kawasaki disease. J Pediatr. 239:11–4. DOI: 10.1016/j.jpeds.2021.08.069. PMID: 34454952. PMCID: PMC8388142.

7. Kang JM, Kim YE, Huh K, Hong J, Kim DW, Kim MY, et al. 2021; Reduction in Kawasaki disease after nonpharmaceutical interventions in the COVID-19 era: a nationwide observational study in Korea. Circulation. 143:2508–10. DOI: 10.1161/CIRCULATIONAHA.121.054785. PMID: 34092115. PMCID: PMC8212882.

8. Dillon MJ, Eleftheriou D, Brogan PA. 2010; Medium-size-vessel vasculitis. Pediatr Nephrol. 25:1641–52. DOI: 10.1007/s00467-009-1336-1. PMID: 19946711. PMCID: PMC2908435.

9. Sag E, Batu ED, Ozen S. 2017; Childhood systemic vasculitis. Best Pract Res Clin Rheumatol. 31:558–75. DOI: 10.1016/j.berh.2017.11.009. PMID: 29773273.

10. Grisaru S, Yuen GW, Miettunen PM, Hamiwka LA. 2010; Incidence of Wegener's granulomatosis in children. J Rheumatol. 37:440–2. DOI: 10.3899/jrheum.090688. PMID: 20032105.

11. Schnabel A, Hedrich CM. 2019; Childhood vasculitis. Front Pediatr. 6:421. DOI: 10.3389/fped.2018.00421. PMID: 30687686. PMCID: PMC6335362.

12. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. 1994; Takayasu arteritis. Ann Intern Med. 120:919–29. DOI: 10.7326/0003-4819-120-11-199406010-00004. PMID: 7909656.

13. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. 2005; Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum. 53:93–9. DOI: 10.1002/art.20928. PMID: 15696553.

14. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. 1994; Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37:187–92. DOI: 10.1002/art.1780370206. PMID: 8129773.

15. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. 2006; EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 65:936–41. DOI: 10.1136/ard.2005.046300. PMID: 16322081. PMCID: PMC1798210.

16. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. 2010; EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 69:798–806. DOI: 10.1136/ard.2009.116657. PMID: 20413568.

17. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2013; 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65:1–11. DOI: 10.1002/art.37715. PMID: 23045170.

18. Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al. 2022; 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 81:315–20. DOI: 10.1136/annrheumdis-2021-221795. PMID: 35110333.

19. Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al. 2022; 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 74:400–6. DOI: 10.1002/art.41983. PMID: 35106973.

20. Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. 2022; 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 74:386–92. DOI: 10.1002/art.41982. PMID: 35106968.

21. Zarka F, Veillette C, Makhzoum JP. 2020; A review of primary vasculitis mimickers based on the Chapel Hill Consensus Classification. Int J Rheumatol. 2020:8392542. DOI: 10.1155/2020/8392542. PMID: 32148510. PMCID: PMC7049422.

22. Athreya BH. 1995; Vasculitis in children. Pediatr Clin North Am. 42:1239–61. DOI: 10.1016/S0031-3955(16)40061-1. PMID: 7567194.

23. Ozen S, Sag E. 2020; Childhood vasculitis. Rheumatology (Oxford). 59(Suppl 3):iii95–100. DOI: 10.1093/rheumatology/kez599. PMID: 32348513.

24. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. 2017; Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 135:e927–99. Erratum in: Circulation 2019;140:e181-4.

25. Dallaire F, Fortier-Morissette Z, Blais S, Dhanrajani A, Basodan D, Renaud C, et al. 2017; Aspirin dose and prevention of coronary abnormalities in Kawasaki disease. Pediatrics. 139:e20170098. DOI: 10.1542/peds.2017-0098. PMID: 28562282.

26. Saulsbury FT. 1999; Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 78:395–409. DOI: 10.1097/00005792-199911000-00005. PMID: 10575422.

27. Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, et al. 2019; European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford). 58:1607–16. DOI: 10.1093/rheumatology/kez041. PMID: 30879080.

28. Morishita K, Brown K, Cabral D. 2015; Pediatric vasculitis: advances in treatment. Curr Opin Rheumatol. 27:493–9. DOI: 10.1097/BOR.0000000000000203. PMID: 26147755.

29. Phillip R, Luqmani R. 2008; Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 26(5 Suppl 51):S94–104.

30. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, et al. 2012; Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatr Nephrol. 27:933–9. DOI: 10.1007/s00467-012-2106-z. PMID: 22311342.

31. Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al. 2005; Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 35:143–53. DOI: 10.1016/j.semarthrit.2005.08.007. PMID: 16325655.

32. Meadow SR. 1978; The prognosis of Henoch Schoenlein nephritis. Clin Nephrol. 9:87–90.

33. Haroon M. 2005; Should children with Henoch-Schonlein purpura and abdominal pain be treated with steroids? Arch Dis Child. 90:1196–8. DOI: 10.1136/adc.2005.077743. PMID: 16243882. PMCID: PMC1720164.

34. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, et al. 2010; Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child. 95:871–6. DOI: 10.1136/adc.2009.167874. PMID: 20371584.

35. Lei WT, Tsai PL, Chu SH, Kao YH, Lin CY, Fang LC, et al. 2018; Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database. Pediatr Rheumatol Online J. 16:25. DOI: 10.1186/s12969-018-0247-8. PMID: 29661187. PMCID: PMC5902957.

36. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, et al. 2010; Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child. 95:877–82. DOI: 10.1136/adc.2009.182394. PMID: 20852275.

37. Chang WL, Yang YH, Wang LC, Lin YT, Chiang BL. 2005; Renal manifestations in Henoch-Schönlein purpura: a 10-year clinical study. Pediatr Nephrol. 20:1269–72. DOI: 10.1007/s00467-005-1903-z. PMID: 15947991.

38. Lu S, Liu D, Xiao J, Yuan W, Wang X, Zhang X, et al. 2015; Comparison between adults and children with Henoch-Schönlein purpura nephritis. Pediatr Nephrol. 30:791–6. DOI: 10.1007/s00467-014-3016-z. PMID: 25481021.

39. Rieu P, Noël LH. 1999; Henoch-Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations. Ann Med Interne (Paris). 150:151–9.

40. Ghrahani R, Ledika MA, Sapartini G, Setiabudiawan B. 2014; Age of onset as a risk factor of renal involvement in Henoch-Schönlein purpura. Asia Pac Allergy. 4:42–7. DOI: 10.5415/apallergy.2014.4.1.42. PMID: 24527410. PMCID: PMC3921867.

41. Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, García-Fuentes M, González-Gay MA. 1997; Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum. 40:859–64. DOI: 10.1002/art.1780400513. PMID: 9153547.

42. Soylemezoglu O, Ozkaya O, Ozen S, Bakkaloglu A, Dusunsel R, Peru H, et al. 2009; Henoch-Schönlein nephritis: a nationwide study. Nephron Clin Pract. 112:c199–204. DOI: 10.1159/000218109. PMID: 19439991.

43. Shi D, Chan H, Yang X, Zhang G, Yang H, Wang M, et al. 2019; Risk factors associated with IgA vasculitis with nephritis (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: a meta-analysis. PLoS One. 14:e0223218. DOI: 10.1371/journal.pone.0223218. PMID: 31574112. PMCID: PMC6772070.

44. Breda L, Carbone I, Casciato I, Gentile C, Grasso EA, di Donato G, et al. 2021; Epidemiological and clinical aspects of immunoglobulin A vasculitis in childhood: a retrospective cohort study. Ital J Pediatr. 47:237. Erratum in: Ital J Pediatr 2022;48:78. DOI: 10.1186/s13052-021-01182-6. PMID: 34911536. PMCID: PMC8672591.